- Addex Provides Corporate Update and Financial Guidance
- Addex and Indivior Extend Research Term of Substance Use Disorder GABAB Positive Allosteric Modulator Discovery Collaboration
- Addex Reports Q3 2022 Financial Results and Provides Corporate Update
- Addex Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
- Addex Therapeutics to Report Third Quarter 2022 Financial Results and Host Conference Call on November 11, 2022
- Addex Increases Issued Share Capital to Create Treasury Shares
- Addex to Present at the Sachs Associates 22nd Annual Biotech in Europe Forum & Baader Investment Conference
- Addex Reports 2022 Half Year and Second Quarter Financial Results and Provides Corporate Update
- Addex and Indivior Extend GABAB Positive Allosteric Modulator Research Collaboration for Substance Use Disorders
- Addex Therapeutics to Report Half-Year 2022 Financial Results and Host Conference Call on August 18, 2022
Addex Therapeutics Ltd (ADXN:SWX) closed at 0.193, 91.85% above the 52 week low of 0.1006 set on Dec 30, 2022.
0.1006Dec 30 20220.94Feb 17 2022
Markit short selling activity
|Market cap||22.15m CHF|
|EPS (TTM)||-0.5532 |
Data delayed at least 15 minutes, as of Jan 30 2023 16:31 GMT.